Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | PPARA | Q07869 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213052 | 0.95 | L3MBTL1 (0.79) | L3MBTL1GAAPPARAHSD17B10MAPT | |
| SCHEMBL7568345 | 0.93 | GAA (0.80) | L3MBTL1GAAPPARAHSD17B10MAPT | |
| SCHEMBL13348918 | 0.93 | GAA (0.80) | L3MBTL1GAAPPARAHSD17B10MAPT | |
| SCHEMBL2213697 | 0.91 | L3MBTL1 (0.72) | L3MBTL1GAAPPARAHSD17B10MAPT | |
| SCHEMBL20148862 | 0.87 | L3MBTL1 (0.79) | L3MBTL1GAAHSD17B10MAPTALDH1A1 | |
| SCHEMBL29867708 | 0.87 | L3MBTL1 (0.58) | L3MBTL1GAAPPARAHSD17B10MAPT | |
| SCHEMBL18868405 | 0.87 | L3MBTL1 (1.00) | L3MBTL1GAAMAPTALDH1A1MAOB | |
| SCHEMBL31448501 | 0.87 | PPARA (0.65) | L3MBTL1GAAPPARALMNAFFAR1 | |
| SCHEMBL16256387 | 0.86 | PPARA (0.58) | L3MBTL1GAAPPARALMNAFFAR1 | |
| SCHEMBL7928218 | 0.86 | L3MBTL1 (0.76) | L3MBTL1GAAHSD17B10MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720134-A1 | ANTI-CEACAM5/6 DUAL-BINDING ANTIBODIES | Nona Biosciences (Suzhou) Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4705354-A1 | ANTI-CEACAM5 ANTIBODIES | Nona Biosciences (Suzhou) Co., Ltd. (CN) | 2026-03-11 | — | — | EP | claimed |
| EP-4688000-A1 | ANTIBODY DRUG CONJUGATES | CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | claimed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | claimed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | claimed |
| US-20250009890-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | TAMBO, INC. | 2025-01-09 | — | — | US | claimed |
| WO-2024250925-A1 | ANTI-CEACAM5 ANTIBODIES | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2024-12-12 | — | — | WO | claimed |
| WO-2024229427-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2006031653-A2 | HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4 ANTIBODY / CALICHEAMICIN CONJUGATES | WYETH (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060002942-A1 | Calicheamicin conjugates | WYETH (US) | 2006-01-05 | — | — | US | claimed |
| WO-2005089808-A2 | ANTIBODY CALICHEAMICIN CONJUGATES | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089807-A2 | ANTIBODY CALICHEAMICIN CONJUGATES FOR PASSIVE TARGETING | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089809-A2 | CALICHEAMICIN CONJUGATION BY ANTIBODY DEGLYCOSYLATION | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1507556-A2 | CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | Wyeth Holdings Corporation (US) | 2005-02-23 | — | — | EP | claimed |
| US-20040192900-A1 | incubating cytotoxic drug derivatives and proteinaceous carrier in non-nucleophilic, protein-compatible, buffered solution, then chromatically separating; higher loading and reduced low conjugate fraction | WYETH HOLDINGS CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-20040082764-A1 | Complex of antibodic and antibiotic with carrier | WYETH HOLDINGS CORPORATION | 2004-04-29 | — | — | US | claimed |
| WO-2003092623-A2 | CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| US-5712374-A | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates | AMERICAN CYANAMID COMPANY (US) | 1998-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | L3MBTL1 1408/4885GAA 3358/4885PPARA 2209/4885 |
| US-20060002942-A1 | Calicheamicin conjugates | CLSPN, CALU, CALR | L3MBTL1 1540/4885GAA 216/4885PPARA 4502/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | L3MBTL1 2863/4885GAA 3593/4885PPARA 4154/4885 |
| US-20250009890-A1 | TRANS-CYCLOOCTENE-MODIFIED BISPECIFIC ANTIBODIES | FCGR3B, PDCD10, PDCD1 | L3MBTL1 810/4885GAA 2564/4885PPARA 3840/4885 |
| US-20040082764-A1 | Complex of antibodic and antibiotic with carrier | CD22, CD2BP2, CLSPN | L3MBTL1 2451/4885GAA 551/4885PPARA 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.